
Hims & Hers Health stock up 578% since 2022, still undervalued with strong growth forecast to $9B revenue by 2030.
Hims & Hers Health has surged 578% since June 2022, yet remains undervalued despite improved fundamentals. The company is projected to reach $3.5 billion in revenue by 2026 and potentially $9 billion by 2030, driven by GLP-1 adoption, peptide product...


